|
|
||||||||||||||
|
|
|||||||||||||||
|
British Journal of Ophthalmology 2005;89:1522-1528; doi:10.1136/bjo.2005.074716 Copyright © 2005 by the BMJ Publishing Group Ltd.
Choroidal neovascularisation in pathological myopia: an update in managementW-M Chan1,2, M Ohji3, T Y Y Lai1, D T L Liu2, Y Tano3, D S C Lam1,2
1 Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong, Peoples Republic of China
Correspondence to:
Choroidal neovascularisation (CNV) secondary to pathological myopia is an important cause of significant visual impairment in young and middle aged adults globally and is particularly prevalent in Asian populations. In the past few years, there have been rapid advancements in the different treatments for myopic CNV. The purpose of this perspective is to give an overview of the natural history of myopic CNV and the various treatment options including laser photocoagulation, photodynamic therapy, submacular surgery, and macular translocation surgery. Future directions in the management of myopic CNV are also discussed.
Abbreviations: AMD, age related macular degeneration; CNV, choroidal neovascularisation; FA, fluorescein angiography; ICG-A, indocyanine green angiography; LMT, limited macular translocation; MfERG, multifocal electroretinogram; OCT, optical coherence tomography; RPE, retinal pigment epithelium; VA, visual acuity; VEGF, vascular endothelial growth factor Keywords: myopia; choroidal neovascularisation; photodynamic therapy; surgery; macular translocation This article has been cited by other articles:
|
||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |